Adrenal cortical imaging with I-131 NP-59 SPECT-CT

Clinical Nuclear Medicine

Volumn 35, Issue 11, 2010, Pages 865-869

  Wong, Ka Kit ^a   Komissarova, Maria ^a   Avram, Anca M ^a   Fig, Lorraine M ^b   Gross, Milton D ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

adrenal nodule; Conn syndrome; Cushing syndrome; SPECT CT

Indexed keywords

6BETA IODOMETHYL 19 NORCHOLEST 5(10) EN 3BETA OL I 131;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX HYPERFUNCTION; ADRENAL DISEASE; ADRENAL HYPERPLASIA; ADRENAL SCINTISCANNING; ADULT; AGED; ANATOMICAL VARIATION; ARTICLE; CASE REPORT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; HUMAN; INTESTINE FUNCTION; MALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

19-IODOCHOLESTEROL; ADRENAL CORTEX; ADULT; AGED; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77958526383     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3181f4a16d     Document Type: Article

References (24)

1. Avram AM, Fig LM, Gross MD. Adrenal gland scintigraphy. Semin Nucl Med. 2006;36:212-227.
2. Kloos R, Gross MD, Francis I, et al. Incidentally discovered adrenal masses. Endocr Rev. 1995;16:460-484.
3. Lockhart ME, Smith JK, Kenney PJ. Imaging of adrenal masses. Eur J Radiol. 2002;41:95-112.
4. Korobkin M, Brodeur FJ, Francis IR, et al. CT time-attenuation washout curves of adrenal adenomas and nonadenomas. Am J Roentgenol. 1998;170: 747-752.
5. NIH state-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma"). NIH Consens State Sci Statements. 2002;19:1-25.
6. Szolar DH, Korobkin M, Reittner P, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology. 2005;234:479-485.
7. Mansmann G, Lau J, Balk E, et al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev. 2004;25:309-340.
8. Kloos RT, Korobkin M, Thompson NW, et al. Incidentally discovered adrenal masses. Cancer Treat Res. 1997;89:263-292.
9. Bardet S, Rohmer V, Murat A, et al. 131I-6 beta-iodomethylnorcholesterol scintigraphy: an assessment of its role in the investigation of adrenocortical incidentalomas. Clin Endocrinol. 1996;44:587-596.
10. Volpe C, Enberg U, Sjögren A, et al. The role of adrenal scintigraphy in the preoperative management of primary aldosteronism. Scand J Surg. 2008;97: 248-253.
11. White ML, Gauger PG, Doherty GM, et al. The role of radiologic studies in the evaluation and management of primary hyperaldosteronism. Surgery. 2008;144:926-933.
12. Izaki H, Fukumori T, Takahashi M, et al. Indications for laparoscopic adrenalectomy for non-functional adrenal tumor with hypertension: usefulness of adrenocortical scintigraphy. Int J Urol. 2006;13:677-681.
13. Yu KC, Alexander HR, Ziessman HA, et al. Role of preoperative iodocholesterol scintiscanning in patients undergoing adrenalectomy for Cushing's syndrome. Surgery. 1995;118:981-986.
14. Dwamena BA, Kloos RT, Fendrick AM, et al. Diagnostic evaluation of the adrenal incidentaloma: decision and cost-effectiveness analyses. J Nucl Med. 1998;39:707-712.
15. Buck AK, Nekolla S, Ziegler S, et al. SPECT/CT. J Nucl Med. 2008;49: 1305-1319.
16. Sarkar SD, Beierwaltes H, Ice RD, et al. A new and superior adrenal scanning agent, NP-59. J Nucl Med. 1975;16:1038-1042.
17. Kazerooni EA, Sisson JC, Shapiro B, et al. Diagnostic accuracy and pitfalls of [iodine-131]6-beta-iodomethyl-19-norcholesterol (NP-59) imaging. J Nucl Med. 1990;31:526-534.
18. Kloos RT, Gross MD, Shapiro B, et al. Diagnostic dilemma of small incidentally discovered adrenal masses: role for 131I-6 beta- iodomethylnorcholesterol scintigraphy. World J Surg. 1997;21:36-40.
19. Hwang I, Balingit AG, Georgitis WJ, et al. Adrenocortical SPECT using iodine-131 NP-59. J Nucl Med. 1998;39:1460-1463.
20. Ishimura J, Kawanaka M, Fukuchi M. Clinical application of SPECT in adrenal imaging with iodine-131 6 beta-iodomethyl-19-norcholesterol. Clin Nucl Med. 1989;14:278-281.
21. Imperiale A, Olianti C, Mannelli M, et al. Tomographic evaluation of [131I] 6beta-iodomethyl-norcholesterol standardised uptake trend in clinically silent monolateral and bilateral adrenocortical incidentalomas. Q J Nucl Med Mol Imaging. 2005;49:287-296.
22. La Cava G, Imperiale A, Olianti C, et al. SPECT semiquantitative analysis of adrenocortical (131)I-6 beta iodomethyl-norcholesterol uptake to discriminate subclinical and preclinical functioning adrenal incidentaloma. J Nucl Med. 2003;44:1057-1064.
23. Chen Y, Wei C, Chen P, et al. Seeking the invisible: I-131 NP-59 SPECT/CT for primary hyperaldosteronism. Kidney Int. 2009;75:663.
24. Yen RF, Wu VC, Liu KL, et al. 131I-6b-iodomethyl-19-norcholesterol SPECT/CT for primary aldosteronism patients with inconclusive adrenal venous sampling and CT results. J Nucl Med. 2009;50:1631-1637.